Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
It is a TROP2 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s proprietary DXd ADC technology, ...
Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the ...
Our pipeline is advancing and expanding ... related to business development transactions with Curon Biopharmaceutical and Daiichi Sankyo. Third quarter results Merck, with multiple facilities ...
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
Modular Devices is excited to announce the addition of David Frank as Fractional Chief Commercial Officer, reinforcing the company's commitment to strategic growth and leadership within the cleanroom ...
Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...
Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...
Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET. Company Participants. Hiroyuki Okuzawa - Representative Director, Presi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback